ArticleNature communications2020
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- PRR11 expression in early ER+/HER2-low breast cancer: Association with estrogen receptor positivity and exploratory analysis of prognostic significance.Oncology letters · 2026Article
- PRR11 as a newly identified oncogenic driver in retinoblastoma.Science China. Life sciences · 2026Article
- Article
- Abnormal levels of miRNA in pancreatic cancer are linked to tumor progression by regulating the translation of tumor-associated mRNA.Annals of medicine · 2025Review
- BLID is a drug-responsive target of FOXO3a and multi-omics analysis reveals survival mechanisms and therapeutic vulnerabilities in BLID-deficient breast cancer cells.Oncology letters · 2025Article
- PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1/S Progression and Epithelial-Mesenchymal Transition.Cancer medicine · 2025Article
- Complex rearrangements fuel ERNature · 2025Article
- GRK2-mediated AKT activation controls cell cycle progression and G2 checkpoint in a p53-dependent manner.Cell death discovery · 2024Article
- Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.Current issues in molecular biology · 2024Article
- A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma.Redox biology · 2024Article
- Overexpression of COL11A1 confers tamoxifen resistance in breast cancer.NPJ breast cancer · 2024Article
- Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2024Article
- Article
- Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer.Cell death & disease · 2023Article
- Article
- Ligand-independent activation of platelet-derived growth factor receptor β promotes vitreous-induced contraction of retinal pigment epithelial cells.BMC ophthalmology · 2023Article
- BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer.Cell death and differentiation · 2023Article
- PRR11 in Malignancies: Biological Activities and Targeted Therapies.Biomolecules · 2022Review
- Article
- Identification of proline-rich protein 11 as a major regulator in mouse spermatogonia maintenance via an increase in BMI1 protein stability.Molecular biology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Kyung-Min LeeHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0001-8381-2423
Angel L Guerrero-ZotanoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.ORCID 0000-0003-0318-9120
Alberto ServettoHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Dhivya R SudhanHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Chang-Ching LinHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Luigi FormisanoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Valerie M JansenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Paula González-EricssonBreast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.ORCID 0000-0002-6292-6963
Melinda E SandersBreast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Thomas P StrickerBreast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Ganesh RajDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Kevin M DeanDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0003-0839-2320
Reto FiolkaDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0002-4636-5000
Lewis C CantleyMeyer Cancer Center, Weill Cornell Medicine College, New York, NY, 10065, USA.ORCID 0000-0002-1298-7653
Ariella B HankerHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID 0000-0002-8655-8341
Carlos L ArteagaHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Carlos.Arteaga@UTSouthwestern.edu.ORCID 0000-0003-0870-9586
The University of Texas Southwestern Medical Center · USBreast Cancer Research Foundation · USVanderbilt University Medical Center · USCornell University · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MRole of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2MProject 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI SCHAFFER, CHRIS B · 2016 to 2020
$10.2MPrune Belly Syndrome: Mechanisms of Filamin A MutationsR01DK127589 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BAKER, LINDA A., QIN, JUN · 2020 to 2024
$2.5MRole of HER2 mutations in breast cancer progression and response to targeted therapiesR01CA224899 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ARTEAGA, CARLOS L · 2018 to 2022
$1.8MNCI NIH HHS K12 CA090625NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA224899NCI NIH HHS R35 CA197588NCI NIH HHS U54 CA210184NIDDK NIH HHS R01 DK127589
Abstract
The 17q23 amplicon is associated with poor outcome in ER
Indexed as
AnimalsBreast NeoplasmsCell Line, TumorCell ProliferationClass I Phosphatidylinositol 3-KinasesDisease Models, AnimalDrug Resistance, NeoplasmEstrogen AntagonistsEstrogen Receptor ModulatorsEstrogensFemaleGene Expression Regulation, NeoplasticHumansInsulinMice, NudePhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-KinasesEstrogen AntagonistsEstrogen Receptor ModulatorsEstrogensInsulinPhosphatidylinositol 3-KinasesPIK3CA protein, humanProtein Kinase InhibitorsProteinsPRR11 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.